198 related articles for article (PubMed ID: 1845126)
1. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
Barrett N; Eder G; Dorner F
Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
[TBL] [Abstract][Full Text] [Related]
2. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
Pincus SH; Messer KG; Hu SL
J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
4. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
5. Adenovirus vectored vaccines.
Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
[TBL] [Abstract][Full Text] [Related]
6. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.
Girard M; van der Ryst E; Barré-Sinoussi F; Nara P; Tartaglia J; Paoletti E; Blondeau C; Jennings M; Verrier F; Meignier B; Fultz PN
Virology; 1997 May; 232(1):98-104. PubMed ID: 9185593
[TBL] [Abstract][Full Text] [Related]
7. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
Parry C; McLain L; Dimmock NJ
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
[TBL] [Abstract][Full Text] [Related]
8. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
9. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA; Schwartz DH; Fabry JA; Lieberman J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
[TBL] [Abstract][Full Text] [Related]
10. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
[TBL] [Abstract][Full Text] [Related]
11. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
12. Prospects for an AIDS vaccine.
Girard M
Cancer Detect Prev; 1990; 14(3):411-3. PubMed ID: 2117487
[TBL] [Abstract][Full Text] [Related]
13. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
[TBL] [Abstract][Full Text] [Related]
15. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
[No Abstract] [Full Text] [Related]
16. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
[TBL] [Abstract][Full Text] [Related]
17. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
[TBL] [Abstract][Full Text] [Related]
18. Current approaches to vaccination against human immunodeficiency viruses.
Gluckman JC; Yagello M; Bahraoui E; Girard M
Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
[No Abstract] [Full Text] [Related]
19. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
20. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
Klaniecki J; Dykers T; Travis B; Schmitt R; Wain M; Watson A; Sridhar P; McClure J; Morein B; Ulrich JT
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):791-8. PubMed ID: 1742074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
